TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
|
Press Release2025, September 22 08:00 a.m. TME Pharma announces date of publication of half year results and CEO share purchase 2025, September 01 08:00 a.m. TME Pharma completes August financing and publishes cash position 2025, August 25 08:00 a.m. TME Pharma to raise EUR 500k through new bond issue and receives new notice of shareholding |
EventsNEAUX CANCER 4th ANNUAL CAGLA CONFERENCE
Aram Mangasarian Latest Analyst ReportInvest Securities |